If levothyroxine is doing its job to balance thyroid hormone levels, it should not hinder weight loss
The case reports of DVT in GLP-1 users all described successful treatment with anticoagulants
Based on our hypothesis that GLP-1 analogs might be superior to DPP-4 inhibitors for pasireotide-induced hyperglycemia, we switched from alogliptin 25 mg daily to dulaglutide 0.75 mg weekly, while other antidiabetic drugs remained unchanged
Oral GLP-1s and New Formulations: The December 2025 approval of oral semaglutide (Wegovy pill) and the anticipated approval of orforglipron (Eli Lilly's non-peptide oral GLP-1) in 2026 will expand the patient pool significantly
At $969 monthly without insurance, and with many insurance plans excluding weight loss medication coverage entirely, brand-name options remain financially out of reach for a large portion of the population that could achieve meaningful health improvements through treatment
Work with a healthcare provider to develop a gradual taper schedule, moving from your therapeutic dose to lower doses over 48 weeks